Prescribing information

 

   

For patients on ICS monotherapy, ATECTURA® BREEZEHALER® (indacaterol acetate/mometasone furoate inhalation powder) long-acting beta2-agonist (LABA)/inhaled corticosteroid (ICS) (IND/MF) is available in three dierent doses: low, medium and high*.1
 

 

How to use the BREEZHALER device

Watch the following video to learn how to use the BREEZHALER.

 

 

*ATECTURA BREEZHALER high-dose = IND/MF 150/320 μg (once-daily); ATECTURA BREEZHALER medium-dose = IND/MF 150/160 μg (once-daily); ATECTURA BREEZHALER low-dose = IND/MF 150/80 μg (once-daily).

IND, indacaterol; MF, mometasone furoate; AE, adverse event; SAE, serious adverse event.

Reference

  1. ATECTURA BREEZEHALER Summary of Product Characteristics.
     
ATE20-C003 November 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]